Examples of using Labelling and package leaflet in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
Labelling and package leaflet.
The legibility of particulars on the labelling and package leaflet.
The valid Summary of Product Characteristics, labelling and package leaflet are the versions agreed by the Reference Member Stateand Concerned Member States(except France) at day 210 of the decentralised procedure.
The Summary of Product Characteristics, Labelling and Package Leaflet of the Reference Member State should be amended.
The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
Therefore the PRAC considered that this information should be added to the relevant sections of the SmPC, labelling and package leaflet.
(d) the approved text of the labelling and package leaflet.
During their 13-16 November 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Ciprofloxacin Nycomed and associated names, that the objections raised by Norway and Sweden should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
(e) the text to appear in the labelling and package leaflet;
During their July 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Fentanyl- ratiopharm 25/ 50/ 75/ 100 µg/ h Matrixpflaster and associated names, that the objections raised by France should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing.
On 3 May 2007, the European Commission presented to the EMEA a referral under Article 30 of Directive 2001/ 83/ EC, as amended, in order toharmonise the nationally authorised Summaries of Product Characteristics(SPC), Labelling and Package Leaflet of the medicinal product Efexor depot.
The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing.
During their April 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the objections raised by Spain could be agreed and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
The Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing.
The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved at day 90 during the Coordination group procedure.
The CHMP gave a positive opinion on 30 May 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Zyrtec and associated names.
The valid Summary of Product Characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure as mentioned in Annex III.
The CHMP gave a positive opinion on 22 February 2007 recommending the harmonisation of the SPC, labelling and package leaflet for Xefo and associated names.
The valid Summary of Product Characteristics, labelling and package leaflet are the versions agreed by the Reference Member Stateand Concerned Member States(except France and Sweden) at day 90 of the mutual recognition procedure.
The revised Product Information(Summary of Product Characteristics, Labelling and Package Leaflet) is set out in Annex II of the Opinion.
The CHMP has therefore recommended the granting of the Marketing Authorisation(s) and the amendment of the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State.
It must not contradict the summary of product characteristics, labelling and package leaflet of the medicinal product, as approved by the competent authorities.
A positive opinion was therefore adopted by consensus on 24 April 2008 and the grounds for opinion,the conditions of the Marketing Authorisation and the amended SPC, labelling and package leaflet of the relevant Member State were annexed.
In addition, other amendments to the Summary of Product Characteristics, labelling and package leaflet not in relation with the outcome of the referral procedure were included in accordance with the Guideline on SPC, excipient guideline and the latest Quality Review of Documents templates.
The CHMP gave a positive opinion on 24 July 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Ciprofloxacin Bayer and associated names.
It mustshall not contradict the summary of product characteristics, labelling and package leaflet of the medicinal product, as approved by the competent authorities.